In our 41 CML bone marrow samples, although a gain of bcr-abl amplification, mutation, and secondary chromosomal changes were found to be associated with the development of imatinib mesylate resistance (p = 0.002, p<0.001, p = 0.001, respectively), none of them showed a statistically significant correlation with AQP5 expression (Table S1). Here, AQP5 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.